Ultragenyx Pharma (RARE) Prices 4.44M Share Common Offering at $90/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Appleās foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Ultragenyx Pharma (RARE) PT Raised to $116 at Cowen
October 28, 2020 6:59 AM EDTCowen analyst Yaron Werber raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $116.00 (from $90.00) while maintaining an Outperform rating.
The analyst commented, "RARE reported Q3:20 earnings with OpEx of $132M v our $128M estimates & steady growth in sales of Crysvita & Dojolvi.... More
Ultragenyx Pharma (RARE) PT Raised to $105 at Wedbush
October 28, 2020 6:28 AM EDTWedbush analyst Laura Chico raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $105.00 (from $97.00) while maintaining a Outperform rating.... More
Ultragenyx Pharma (RARE) PT Raised to $121 at Barclays
October 28, 2020 4:59 AM EDTBarclays raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $121.00 (from $99.00) while maintaining a Overweight rating.... More
Ultragenyx Pharma (RARE) Tops Q3 EPS by 14c, Revenues Beat
October 27, 2020 4:45 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.13), $0.14 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $81.5 million versus the consensus estimate of $53.89 million.
Third quarter 2020 total revenue of $81.5 million and Crysvita revenue of $37.3 millionIncreased lower end of... More
